| Enriched cancer pathway | Genes under regulation | P value |
|---|
| Hippo signaling pathway |
12 genes: MPP5, FRMD6, PPP1CB, DLG2, TEAD1, SMAD4, BMPR1A, FZD3, FZD6, CTNNA3, CTNNA1, NKD1
|
0.0002793 |
| Adherens junction |
8 genes: CTNNA1, EGFR, EP300, CTNNA3, IGF1R, SMAD4, PTPRF, TJP1
|
0.0003005 |
| Tight junction |
10 genes: EXOC3, CTNNA1, MAGI3, CTNNA3, ASH1L, EXOC4, MPP5, TJP1, CASK, MAGI2
|
0.001164 |
| Wnt signaling pathway |
9 genes: EP300, DAAM1, SMAD4, PPARD, PPP3CB, CHD8, FZD3, FZD6, NKD1
|
0.009264 |
| Lysine degradation |
4 genes: DLST, SETD2, OGDH, ASH1L
|
0.01922 |
| Focal adhesion |
10 genes: EGFR, IGF1R, ITGA1, LAMC1, PPP1R12A, PPP1CB, PARVA, PTK2, SOS2, VEGFB
|
0.01969 |
| Long.term potentiation |
5 genes: EP300, PPP1R12A, PPP1CB, PPP3CB, CACNA1C
|
0.02399 |
| Citrate cycle .TCA cycle. |
3 genes: DLST, OGDH, SUCLA2
|
0.03239 |